.jpeg)
2026-05-26 04:51:38
A comprehensive analysis of the synergistic mechanisms, global clinical research, safety management, and application of the Ixazomib and Pomalidomide combination for relapsed/refractory multiple myeloma.
2026-05-25 04:22:45
Discover how Etrasimod (Velsipity) works by sequestering lymphocytes to achieve mucosal healing in moderate-to-severe Ulcerative Colitis. Explore its mechanism, efficacy, and future in Crohn's Disease.
2026-05-25 04:15:46
Can topical Delgocitinib (JAK inhibitor) restore skin pigment? Explore the science behind repigmentation, current clinical trial status, and global access for vitiligo patients.
2026-05-25 04:05:18
Explore the breakthrough of Sotorasib (AMG-510), the first approved KRAS G12C inhibitor. Detailed clinical trial data, dosage guidelines, and global pricing insights for patients in Hong Kong, Macau, and worldwide.
2026-05-22 05:36:56
Deciphering the dual role of Reactive Oxygen Species (ROS) in cancer, analyzing oxidative stress mechanisms, and exploring the latest research on natural compounds like curcumin in oncology.
2026-05-22 04:06:55
LONSURF® (Trifluridine/Tipiracil) has become a cornerstone in the later-line treatment of metastatic colorectal cancer. This article explores its origins at Taiho Pharmaceutical, its unique mechanism of action, and the robust global manufacturing network ensuring its quality and availability.
2026-05-22 03:58:23
KOSELUGO® (Selumetinib), a highly selective MEK inhibitor, is now approved for pediatric and adult patients with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This article explores the clinical challenges, dosing strategies, and global market dynamics of this breakthrough targeted therapy.
2026-05-21 06:42:31
Eli Lilly announced FDA approval of Inluriyo (Imlunestrant), an oral estrogen receptor antagonist for ER+, HER2- advanced breast cancer with ESR1 mutations post-endocrine therapy progression.
2026-05-20 04:57:13
A comprehensive guide to Niraparib (Zejula), a once-daily PARP inhibitor for maintaining remission in ovarian, fallopian tube, and peritoneal cancers. Learn about HRD selection, dosing by weight, and critical blood monitoring.
2026-05-20 04:44:25
A guide to Abiraterone, a hormonal therapy for metastatic prostate cancer. Learn about its mechanism in blocking androgen synthesis, dosing with Prednisone, and critical safety protocols for liver health and fetal protection.
2026-05-20 03:01:24
A comprehensive guide to Plerixafor (Mozobil), a CXCR4 antagonist used in stem cell transplantation for Non-Hodgkin's Lymphoma and Multiple Myeloma. Learn about dosage, administration, and critical safety protocols.
2026-05-20 02:43:58
Explore the safety profile of Brensoctib, a first-in-class DPP-1 inhibitor for neutrophil-mediated inflammatory diseases. This guide details the management of dermatological, periodontal, and infection risks during treatment.
